Loading
Motus GI Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 22 Nov 2021.
Motus GI Holdings, Inc.: what insiders have been doing
Motus GI Holdings, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Motus GI Holdings, Inc. has had no insider filing for more than a year; the last one goes back to 11 February 2022.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
12
Thresholds
n/a
Buy Volume
n/a
3 ops. · all time
Sell Volume
n/a
n/a
Financial data
as of FY 2023FY ended December 2023 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$319k
Gross profit-US$250k-78% margin
EBITDA-US$11.4M-3583% margin
Net income-US$12.9M-4033.5% margin
Valuation
P/Book0.0x
Beta-5.57
Balance sheet & cash
Market capUS$638
Total debtUS$2.5M
Free Cash Flow-US$11.3M
Debt / Equity79%
Profitability & ownership
ROE-1069.0%
ROA-62.0%
% insiders0.0%
% institutions0.0%
Last declaration on 11 February 2022
Declarations12 total
175,000 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-22-004067:0
95,000 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-22-004075:0
95,000 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-22-004082:0
106,563 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-22-000692:0
82,500 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-22-000691:0
127,083 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-22-000694:0
90,521 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-22-000690:0
82,500 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-22-000693:0
4,000 shares@ €0.4493100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001213900-21-061013:0
Canonical exit: 17 Feb 2022 (T+90)
10,000 shares@ €0.4586100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001213900-21-061012:0
Canonical exit: 17 Feb 2022 (T+90)
2,000 shares@ €0.4491100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001213900-21-061014:0
Canonical exit: 17 Feb 2022 (T+90)
18,209 shares0Common Stock, par value $0.0001 per shareSEC:0001213900-21-033779:0
12 of 12 declarations
About Motus GI Holdings, Inc.
Motus GI Holdings, Inc. is a U.S.-based medical device company listed on the Nasdaq Capital Market in the United States under the ticker MOTS. The company operates in the gastrointestinal endoscopy niche, with its core value proposition centered on improving colon cleansing during colonoscopy in order to help reduce incomplete procedures, repeat exams, and clinical inefficiencies. Incorporated in Delaware in September 2016, Motus GI built its platform around the proprietary Pure-Vu System, which has received FDA 510(k) clearance and CE Mark approval in Europe for certain product generations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1686850/000121390021015694/f10k2020_motusgiholdings.htm?utm_source=openai))
From an operating perspective, Motus GI is a medical technology company focused on endoscopy solutions that improve clinical outcomes and the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions. Its business model has historically been centered on developing, commercializing, and iterating devices designed to assist with difficult or poorly prepared colonoscopy procedures, a clinically recognized unmet need in hospital and inpatient settings. The company has described the evolution of its product line through a second-generation Pure-Vu platform and, more recently, commercial activity around the Pure-Vu EVS System. That suggests a strategy built on product refreshes and broader procedural adoption, although the company remains a specialized, niche player rather than a large-scale diversified medtech platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1686850/000121390020007971/f10k2019_motusgiholdings.htm?utm_source=openai))
Read moreShow less
Historically, Motus GI was created to address the limitations of colonoscopy when bowel preparation is inadequate. The company previously highlighted Fort Lauderdale, Florida, as its headquarters, and later announced a move of its corporate headquarters to the Greater Boston area in 2020 to improve collaboration and operational efficiency. Its geographic footprint is international at the industrial level, with legacy subsidiaries and activities linked to both the United States and Israel. ([nasdaq.com](https://www.nasdaq.com/press-release/motus-gi-moving-corporate-headquarters-to-greater-boston-area-to-foster-closer?utm_source=openai))
In competitive terms, Motus GI operates in a highly specialized segment where differentiation depends on clinical utility, ease of use, and economic value to providers. Compared with large endoscopy and gastrointestinal device manufacturers, it is a relatively small innovator with a focused solution set rather than a broad product portfolio. Recent notable corporate events include a February 2024 warrant exercise transaction that generated approximately $2.7 million in gross proceeds, underscoring that the company continues to rely on capital-market funding. For equity investors, the ongoing stream of SEC Form 4 insider transactions is relevant because it can provide signals on management and insider alignment in a stock that has historically been volatile and financing-sensitive. ([nasdaq.com](https://www.nasdaq.com/press-release/motus-gi-holdings-inc.-announces-exercise-of-warrants-for-%242.7-million-gross-proceeds?utm_source=openai))
